(Q35835795)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Empowering targeted therapy: lessons from rituximab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Adam J Olszewski

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

1 reference

6 July 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

Science's STKE : signal transduction knowledge environment

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

241

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

pe30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15252219%20AND%20SRC:MED&resulttype=core&format=json

Continuous cultures of fused cells secreting antibody of predefined specificity

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

B cells as therapeutic targets for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

MHC class II isotype-specific signaling complex on human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Caveolae: where incoming and outgoing messengers meet

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Lipid rafts and little caves. Compartmentalized signalling in membrane microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Novel therapies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2412004PE30